Scottish animal healthcare specialist MI:RNA has raised a second tranche of investment to further grow its business in the field of early disease detection.
Founded in 2019 as a spinout from Scotland's Rural College in Edinburgh, the company's technology uses biomarkers and AI-driven modelling to diagnose veterinary disease earlier. Its initial area of focus is on heart disease diagnostics for dogs and cats, and other areas of interest include chronic livestock diseases and canine osteoarthritis diagnosis.
The oversubscribed funding round of $3.6 million (£2.7m) was raised from a collection of existing venture capital investors and two new investment funds. It follows a $4m funding round in July 2024 led by life sciences investment firm NovaQuest.
The funding will be used to accelerate commercial growth in partnership with key multinationals in animal health as MI:RNA further advances its flagship diagnostic platform. Eve Hanks, chief executive and founder of MI:RNA, said it follows what has been a period of rapid expansion and commercial progress for the company.
Related News
- Research partnership targets rising heat stress challenges in dairy sheds
- New sensor being used in the dairy sector to monitor calf health
"Our technology uses biomarkers and advanced modelling to spot health problems in animals earlier than ever before with a simple blood sample," she said. "With this incredible new approach, we can diagnose, monitor, and predict how diseases will develop for happier, healthier pets and a sustainable future for agriculture.
“The opportunity to deploy our diagnostic platform globally through our partner laboratories is taking shape, and this positive support from our investors not only validates the strength of our technology and market approach, it also accelerates our continued development and technological advancement as we work to bring critical diagnostic solutions into the hands of those who need them most."
The company says it expansion into the US has been a "huge success", with the opening of a new research lab facility at the University of Georgia in Athens last year. This has led to wider development and validation work with additional collaborators.
MI:RNA is also partnered with lab networks in the UK and the EU.
In addition to NovaQuest, existing investors taking part in the latest funding round include Kyoritsu Holdings Corporation, VANE, Animal Health Angels, Equity Gap, Gabriel and Scottish Enterprise. The new investors are Holstein UK and AniVC.
“The continued overwhelming support for MI:RNA is a testament to the promise of this company, the team, and this innovative platform," said Brian Axe, partner at NovaQuest Capital Management. "We are excited to see this technology deployed in the market.”
The company employs a team of 36 working across the UK, EU, the US, and the Asia-Pacific region.
In October it appointed Dr Natalie Marks as its new chief veterinary officer, while Rose Jenkins will join next month as chief operating officer. Ms Jenkins has more than 25 years of strategic and operational leadership across complex public and private sector organisations and will guide MI:RNA in its ambition to move towards a fully commercialised offering.
“This is a positive milestone for us that will allow us to scale more quickly, as we work to give animals longer, healthier lives," Ms Hanks added.
Share